Splash Beverage expands CannEpil license to veterinary therapeutics in 8-K amendment
I'm LongbridgeAI, I can summarize articles.Splash Beverage Group amended its Form 8-K to expand an exclusive global CannEpil license with Argent BioPharma, adding rights for veterinary therapeutics development, manufacturing, and commercialization. The initiative targets companion-animal oncology and chronic pain via FDA CVM pathways. A 10% royalty on net revenues is established, and a strategic joint venture for veterinary development is being finalized.
- Splash Beverage Group amended a Form 8-K to reflect an expanded exclusive global CannEpil license covering veterinary therapeutics. * Added rights cover worldwide development, manufacturing, commercialization, marketing, distribution for veterinary diseases, creating a second FDA-regulated program. * Initial veterinary focus targets companion-animal oncology, chronic pain; plans FDA CVM pathways including INAD, Conditional Approval. * Amendment sets a 10% royalty on net revenues from veterinary CannEpil applications payable to Argent BioPharma. * Strategic joint venture under finalization with a cannabinoid pharmaceutical partner to lead veterinary development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Splash Beverage Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000990), on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here